phipps_matt_land

Matt Phipps

Analyst
+1 312 364 8602
Email vCard

Specialties:  Biotechnology

Matt Phipps, Ph.D., a biotechnology analyst, joined William Blair in November 2014, after working as a postdoctoral research fellow at Texas Scottish Rite Hospital for Children. Mr. Phipps earned a Ph.D. in cellular and molecular physiology from the University of Alabama at Birmingham and a B.S in physics in medicine from the University of Notre Dame.

Pieris Pharmaceuticals, Inc.: Initiation of Research Coverage

William Blair & Company initiated research coverage of Pieris Pharmaceuticals, Inc. (PIRS $7.46), a clinical-stage biotech company developing novel therapies using the company’s proprietary Anticalin platform. Learn More

Calithera Biosciences, Inc.: Initiation of Research Coverage

William Blair & Company initiated research coverage of Calithera Biosciences, Inc. (CALA $15.25), a clinical-stage company developing novel cancer therapies targeting changes in tumor cell metabolism. Learn More